Sanofi SA at Cowen HealthCare Conference Transcript
Well, good morning, once again. And we'd like to welcome Sanofi to the Cowen Conference. Representing the company is Bill Sibold, who is Executive Vice President of Sanofi Genzyme, one of the most important parts of the company. And Bill, you were going to make a few comments to start.
Well, thanks, Steve, and thanks for having me here today. Just to set the frame a little bit, since our Capital Markets Day in December, we've talked about our Play to Win approach and we're making, I'd say, great progress there. The strategy really includes 4 key pillars. Focusing on growth, leading with innovation, accelerating efficiencies, and finally reinventing how we do work, and maybe just a couple of comments on the first to focus on growth. And obviously, a key driver of growth for us is Dupixent. And we've really been looking at Dupixent as we've given the guidance that we think this is going to be a greater than EUR 10
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
